Mauna Kea Technologies S.A.
MKEAF
Other OTC0.37
USD
- -
- -
Mauna Kea Technologies S.A.
MKEAF
(Other OTC)
Recent
price
0.37
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Mauna Kea Technologies S.A. (Euronext Growth: ALMKT) develops and commercializes Cellvizio, the real-time in vivo cellular imaging platform based on probe and needle-based confocal laser endomicroscopy (p/nCLE) technology; the platform includes Cellvizio systems, Confocal Miniprobes, software, licenses, and related services such as CellTolerance for food intolerance diagnostics and treatment. Cellvizio enables physicians to visualize cellular structures during endoscopic procedures in specialties including gastroenterology, pulmonology, urology, oncology, neurosurgery, and interventional pulmonology; it supports real-time diagnosis, disease monitoring, treatment guidance, and surgical margin verification. The company generates revenue from system sales (17%), accessories (38%), licenses (26%), and services (19%), with geographic sales distributed across Europe/Middle East/Africa (26%), the United States and Canada (45%), and Asia (29%). Founded in 2000 and headquartered at 9 rue d'Enghien, Paris, France, with a U.S. office in Allston, Massachusetts, Mauna Kea Technologies employs 65 people and trades publicly since 2011. The company maintains strategic partnerships with Johnson & Johnson, Telix Pharmaceuticals, and Tasly Pharmaceutical (via a joint venture in China) to expand Cellvizio applications in robotic surgery, AI-assisted imaging, and therapeutic areas like uro-oncology. In November 2025, Mauna Kea Technologies successfully completed a financial restructuring under safeguard proceedings, exiting with court approval and raising €6 million in new capital; it had mandated investment banks Bucephale Finance and RM Global earlier in 2025 to explore strategic options including M&A, licensing, and commercialization deals, with exclusive negotiations underway for a potential licensing agreement. The company launched CellTolerance in Q4 2024, generating €0.5 million in initial revenue from a pilot center and building a pipeline of 42 commercial opportunities targeting threefold sales growth in 2025; it received NMPA approval in China for its next-generation Cellvizio Gen 3 platform and announced an exclusive U.S. partnership with TaeWoong Medical USA for pancreatic cyst management. Full-year 2024 sales excluding licenses totaled €5.6 million, down 9% year-over-year due to delayed capital equipment sales and stalled China JV revenue, prompting ongoing efforts to extend cash runway through Q1 2026 via cost reductions and investor discussions.
Mauna Kea Technologies Reports FY 2025 Financial Results: Comprehensive Debt Restructuring and Reaccelerating Organic Growth Mark a Transformative 2025
Mauna Kea Technologies Reports Strong Q1 2026 Core Sales Growth
Mauna Kea Technologies Announces 2025 Half-Year Results
Mauna Kea Technologies Unveils CellTolerance, a Subsidiary Dedicated to its Unique Program for the Detection and Treatment of Food Intolerances
Mauna Kea Technologies Reports Full Year 2023 Results and Q1 2024 Sales
Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery